Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMG8K57)

• Drug Name: Cortisone Acetate Drug Info
• Synonyms: Cortone

Indication

Disease Entry	ICD 11	Status	REF
Acne vulgaris	ED80	Approved	[1]
Acute adrenal insufficiency		Approved	[1]
Addison disease	5A74.0	Approved	[1]
Advanced cancer	2A00-2F9Z	Approved	[1]
Allergic rhinitis	CA08.0	Approved	[1]
Angioedema	4A00.15	Approved	[1]
Aspiration pneumonitis		Approved	[1]
Autoimmune haemolytic anaemia	3A20	Approved	[1]
Blepharoconjunctivitis		Approved	[1]
Bursitis		Approved	[1]
Cerebral edema	8D60.1	Approved	[1]
Congenital adrenal hyperplasia	5A71.01	Approved	[1]
Corneal abrasion	NA06.4	Approved	[1]
Corneal ulcer	9A76	Approved	[1]
Crohn disease	DD70	Approved	[1]
Dermatitis herpetiformis	EB44	Approved	[1]
Diamond-Blackfan anemia		Approved	[1]
Disorder of orbital region		Approved	[1]
Epicondylitis		Approved	[1]
Erythema multiforme		Approved	[1]
Exanthem		Approved	[1]
Gingival disorder		Approved	[1]
Granuloma annulare		Approved	[1]
Inflammatory bowel disease	DD72	Approved	[1]
Keratitis		Approved	[1]
Malignant otitis externa caused by Pseudomonas aeruginosa		Approved	[1]
Miliary tuberculosis		Approved	[1]
Multiple sclerosis	8A40	Approved	[1]
Mycosis fungoides	2B01	Approved	[1]
Primary cutaneous T-cell lymphoma		Approved	[1]
Proctitis	DB33.Z	Approved	[1]
Psoriasis	EA90	Approved	[1]
Psoriatic arthritis	FA21	Approved	[1]
Rheumatic heart disease		Approved	[1]
Rosacea	ED90.0	Approved	[1]
Sarcoidosis	4B20.5	Approved	[1]
Serum sickness		Approved	[1]
Severe asthma	CA23	Approved	[1]
Skin disease	EA00-EM0Z	Approved	[1]
Solid tumour/cancer	2A00-2F9Z	Approved	[2]
Systemic lupus erythematosus	4A40.0	Approved	[1]
Tinea corporis	1F28.Y	Approved	[1]
Tinea cruris	1F28.3	Approved	[1]
Ulcerative colitis	DD71	Approved	[1]
Acquired thrombocytopenia		Investigative	[1]
Asthma	CA23	Investigative	[1]
Beta-thalassemia major		Investigative	[1]
Classic Hodgkin lymphoma		Investigative	[1]
Follicular lymphoma	2A80	Investigative	[1]
Iridocyclitis		Investigative	[1]
Rheumatoid arthritis	FA20	Investigative	[1]
Synovitis		Investigative	[1]
Tinea pedis	1F28.2	Investigative	[1]
Trichinellosis		Investigative	[1]
Uveitis	9A96.Z	Investigative	[1]

• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 5745
  ChEBI ID: CHEBI:3897
  CAS Number: CAS 50-04-4
  TTD Drug ID: DMG8K57
  INTEDE Drug ID: DR0385
  ACDINA Drug ID: D00152

Molecule-Related Drug Atlas

Drug(s) Targeting Steroid hormone receptor ERR (ESRR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beclomethasone	DMZPHIK	Allergic rhinitis	CA08.0	Approved	[3]
Auranofin	DMWE2N4	Inflammatory arthritis	FA2Z	Approved	[3]
Loteprednol Etabonate	DM8QTJI	Eye inflammation	9A02	Approved	[3]
Desonide	DMTP2NJ	Allergic rhinitis	CA08.0	Approved	[3]
Fluocinonide	DM65KL8	Exanthem		Approved	[3]
Medrysone	DMJ90O5	Corneal abrasion	NA06.4	Approved	[3]
Halcinonide	DMGLAX1	Exanthem		Approved	[3]
Amcinonide	DMM1JL9	Exanthem		Approved	[3]
Prednicarbate	DMBUNVW	Exanthem		Approved	[3]
Flurandrenolide	DMHCI9S	Exanthem		Approved	[3]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[8]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[9]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[10]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[11]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[12]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[13]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[14]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[15]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[9]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[16]

Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[17]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[18]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[19]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[20]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[21]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[22]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[23]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[24]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[25]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[20]

Drug(s) Metabolized By Cytochrome P450 3A7 (CYP3A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[26]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[20]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[20]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[20]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[27]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[28]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[20]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[20]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[20]
Metronidazole	DMTIVEN	Abscess		Approved	[29]

Drug(s) Metabolized By Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nabumetone	DMAT2XH	Osteoarthritis	FA00-FA05	Approved	[30]
Dehydrocorticosterone	DM48KMB	N. A.	N. A.	Investigative	[6]

Drug(s) Metabolized By Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[31]
Beclomethasone	DMZPHIK	Allergic rhinitis	CA08.0	Approved	[31]
Betamethasone Valerate	DMMIAXO	Dermatological disease	DA24.Y	Approved	[31]
Dehydrocorticosterone	DM48KMB	N. A.	N. A.	Investigative	[6]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Steroid hormone receptor ERR (ESRR)	TTP3UTW	ERR1_HUMAN; ERR2_HUMAN; ERR3_HUMAN	Modulator	[3]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[4]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[5]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[5]
Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2)	DEDH7FP	DHI2_HUMAN	Substrate	[6]
Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)	DEZDRQO	DHI1_HUMAN	Substrate	[6]
Short-chain dehydrogenase/reductase retSDR4 (DHRS7)	DEEXSKI	DHRS7_HUMAN	Substrate	[7]

References

• [1] Cortisone acetate FDA Label
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] Prediction of tacrolimus metabolism and dosage requirements based on CYP3A4 phenotype and CYP3A5(*)3 genotype in Chinese renal transplant recipients. Acta Pharmacol Sin. 2016 Apr;37(4):555-60.
• [5] Comparative pharmacokinetics and metabolism studies in lean and diet- induced obese mice: an animal efficacy model for 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors. Drug Metab Lett. 2011 Jan;5(1):55-63.
• [6] Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species. J Mol Endocrinol. 2005 Aug;35(1):89-101.
• [7] Human DHRS7, promising enzyme in metabolism of steroids and retinoids? J Steroid Biochem Mol Biol. 2016 Jan;155(Pt A):112-9.
• [8] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [9] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [10] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [11] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [12] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [13] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [14] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [15] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [16] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [17] Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
• [18] Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
• [19] Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
• [20] Drug Interactions Flockhart Table
• [21] Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
• [22] Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
• [23] Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
• [24] Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
• [25] Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
• [26] The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
• [27] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [28] Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
• [29] The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
• [30] Reductive metabolism of nabumetone by human liver microsomal and cytosolic fractions: exploratory prediction using inhibitors and substrates as marker probes. Eur J Drug Metab Pharmacokinet. 2015 Jun;40(2):127-35.
• [31] Metabolism of synthetic steroids by the human placenta. Placenta. 2007 Jan;28(1):39-46.